arrow
Y

Yang Luo

national cancer center
H指数:24
被引数:2,465

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Neutrophil Senescence Induced by Tumor-Derived HMGB1 Promotes Hepatocellular Carcinoma Progression through Neutrophil Extracellular Trap-Mediated Suppression of CD8+ T Cell Immunity

肿瘤来源的HMGB1诱导的中性粒细胞衰老通过中性粒细胞胞外陷阱介导的CD8+ T细胞免疫抑制促进肝细胞癌进展

2026-09-110
OA
Adjuvant T-DM1 versus trastuzumab plus pertuzumab for residual disease after neoadjuvant dual HER2 blockade in HER2-positive early breast cancer: a multicenter real-world study

新辅助双HER2阻断后残余疾病患者的T-DM1辅助治疗与曲妥珠单抗联合帕妥珠单抗的比较:一项多中心真实世界研究

2026-08-290
OA
Lerociclib plus fulvestrant in patients with HR+/HER2-locally advanced or metastatic breast cancer who have progressed on prior endocrine therapy: LEONARDA-1 a phase III randomized trial

Lerociclib联合fulvestrant用于接受过先前内分泌治疗并进展的HR+/HER2-局部晚期或转移性乳腺癌患者的治疗:LEONARDA-1一项III期随机试验

2025-01-160
OA
A sonographic endometrial thickness <7 mm in women undergoing in vitro fertilization increases the risk of placenta accreta spectrum

在接受体外受精的妇女中,超声检查子宫内膜厚度 <7毫米会增加胎盘植入的风险。

2024-11-010
OAAI
Efficacy and safety of apatinib combined with dose-dense paclitaxel and carboplatin in neoadjuvant therapy for locally advanced triple-negative breast cancer: A prospective cohort study with propensity-matched analysis

阿帕替尼联合剂量密集紫杉醇和卡铂新辅助治疗局部晚期三阴性乳腺癌的疗效和安全性: 倾向匹配分析的前瞻性队列研究

2023-09-073
OAAI